LCP
PCRX icon

Legacy Capital Partners’s Pacira BioSciences PCRX Stock Holding History

Legacy Capital Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3.15M Sell
41,252
-200
-0.5% -$13.3K 1.04% 30
2021
Q4 		$2.49M Sell
41,452
-228
-0.5% -$12.6K 0.81% 40
2021
Q3 		$2.33M Sell
41,680
-71
-0.2% -$4.09K 0.84% 40
2021
Q2 		$2.53M Sell
41,751
-200
-0.5% -$12.7K 0.91% 35
2021
Q1 		$2.94M Hold
41,951
– – 1.11% 28
2020
Q4 		$2.51M Sell
41,951
-1,400
-3% -$82K 0.98% 32
2020
Q3 		$2.61M Sell
43,351
-200
-0.5% -$11.6K 1.05% 33
2020
Q2 		$2.29M Sell
43,551
-130
-0.3% -$5.43K 0.98% 36
2020
Q1 		$1.47M Sell
43,681
-164
-0.4% -$6.81K 0.73% 43
2019
Q4 		$1.99M Sell
43,845
-700
-2% -$29.7K 0.8% 44
2019
Q3 		$1.7M Sell
44,545
-4,028
-8% -$161K 0.74% 46
2019
Q2 		$2.11M Buy
48,573
+1,025
+2% +$43.5K 0.94% 42
2019
Q1 		$1.81M Sell
47,548
-460
-1% -$18K 0.84% 43
2018
Q4 		$2.06M Buy
48,008
+475
+1% +$22.2K 1.09% 36
2018
Q3 		$2.33M Sell
47,533
-1,055
-2% -$45.6K 1.08% 35
2018
Q2 		$1.56M Sell
48,588
-800
-2% -$27.6K 0.76% 49
2018
Q1 		$1.54M Sell
49,388
-1,105
-2% -$39.3K 0.77% 49
2017
Q4 		$2.31M Buy
50,493
+3,100
+7% +$123K 1.14% 38
2017
Q3 		$1.78M Buy
47,393
+600
+1% +$24.1K 0.94% 43
2017
Q2 		$2.23M Buy
46,793
+3,045
+7% +$141K 1.21% 33
2017
Q1 		$2M Buy
43,748
+3,695
+9% +$160K 1.12% 38
2016
Q4 		$1.29M Buy
40,053
+223
+0.6% +$7.44K 0.78% 47
2016
Q3 		$1.36M Buy
39,830
+16,630
+72% +$652K 0.86% 43
2016
Q2 		$783K Buy
23,200
+100
+0.4% +$4.92K 0.49% 61
2016
Q1 		$1.22M Buy
23,100
+3,050
+15% +$178K 0.79% 46
2015
Q4 		$1.54M Sell
20,050
-600
-3% -$34K 0.99% 37
2015
Q3 		$849K Buy
+20,650
New +$1.26M 0.58% 59

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Legacy Capital Partners's PCRX Position: Q1 2022 in Review

Legacy Capital Partners reduced its Pacira BioSciences (PCRX) stake by 0.48% in Q1 2022, selling an estimated $13.3K and leaving 41,252 shares worth $3.15M. The position accounts for 1.04% of the portfolio, ranked #30.

Legacy Capital Partners first reported a position in PCRX in Q3 2015 and has held it in 27 quarters since. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

  • Legacy Capital Partners held 41,252 shares of Pacira BioSciences worth $3.15M as of Q1 2022.
  • Legacy Capital Partners sold 200 Pacira BioSciences shares in Q1 2022, an estimated $13.3K.
  • Pacira BioSciences made up 1.04% of Legacy Capital Partners's portfolio in Q1 2022, its #30 holding.
  • Legacy Capital Partners first reported a position in Pacira BioSciences in Q3 2015 and has held it in 27 quarters since.
  • 301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on Legacy Capital Partners's 13F filing for Q1 2022, filed 11 Apr 2022.